{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:03Z","timestamp":1791920883752,"version":"4.3.4"},"reference-count":50,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>HIV infection is associated with an increased risk of diffuse large B-cell lymphoma (DLBCL). In this prospective study, we analyzed the evolution of B-cell activating cytokines (interleukin-6 [IL-6], IL-10, and B-cell activating factor [BAFF]) and main functional subsets of circulating B and T cells in 51 patients with HIV-associated DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone). R-CHOP therapy was associated with a decrease of IL-10, whereas IL-6 levels fluctuated, and BAFF levels increased during the first 3\u00a0months and decreased thereafter. We observed a rapid rise in CD19+ B cells composed mostly of na\u00efve B cells whereas marginal zone\u2013like B cells and memory B cells recovered gradually. With a median follow-up of 41\u00a0months, progression-free survival and overall survival at 5 years were 61.8% (95% confidence interval [CI], 47.6-80.4) and 67.4% (95%\u00a0CI, 53.4-85.0), respectively. Progression (17.5%) and sepsis (12.5%) were the main causes of death. Baseline risk factors for death and progression were poor revised International Prognostic Index (P\u00a0=\u00a0.049), natural killer cell lymphopenia (P\u00a0=\u00a0.001), lower proportion of na\u00efve B cells (P\u00a0=\u00a0.017), and higher IL-6 serum levels (P\u00a0=\u00a0.001). Our data suggest that patients treated with R-CHOP for HIV-associated DLBCL have a disturbed peripheral B-cell compartment and that the low pool size of circulating na\u00efve B cells negatively affects their clinical outcome. In an era of development of B-cell\u2013depleting therapies including B-cell\u2013targeting chimeric antigen receptor T cells, assessment of perturbations within nontumoral B-cell counterparts are warranted for risk profiling in HIV-associated DLBCL. This trial was registered at www.ClinicalTrials.gov as #NCT01164436.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014116","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T20:14:16Z","timestamp":1727727256000},"page":"6017-6027","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Immune reconstitution and evolution of B-cell\u2013stimulating cytokines after R-CHOP therapy for HIV-associated DLBCL"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5097-591X","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Li\u00e9vin","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, Hospital of Versailles, Le Chesnay, France"},{"name":"2Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, University of Paris, INSERM U1163, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Maillard","sequence":"additional","affiliation":[{"name":"3M\u00e9decine Intensive et R\u00e9animation, H\u00f4pital Saint-Louis, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houria","family":"Hendel-Chavez","sequence":"additional","affiliation":[{"name":"4Department of Immunology, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Kremlin-Bic\u00eatre, France"},{"name":"5INSERM U1186, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Krzysiek","sequence":"additional","affiliation":[{"name":"4Department of Immunology, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Kremlin-Bic\u00eatre, France"},{"name":"6INSERM UMR 996, Inflammation Microbiome and Immunosurveillance, Paris-Saclay University, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Lancar","sequence":"additional","affiliation":[{"name":"6INSERM UMR 996, Inflammation Microbiome and Immunosurveillance, Paris-Saclay University, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Algarte-Genin","sequence":"additional","affiliation":[{"name":"7Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Sorbonne Universit\u00e9, INSERM UMR-S 1136, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[{"name":"7Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Sorbonne Universit\u00e9, INSERM UMR-S 1136, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"7Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Sorbonne Universit\u00e9, INSERM UMR-S 1136, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Taoufik","sequence":"additional","affiliation":[{"name":"4Department of Immunology, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Kremlin-Bic\u00eatre, France"},{"name":"5INSERM U1186, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-7173","authenticated-orcid":false,"given":"Caroline","family":"Besson","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Hospital of Versailles, Le Chesnay, France"},{"name":"8Universit\u00e9 Versailles Saint Quentin en Yvelines, Universit\u00e9 Paris-Saclay, Montigny le Bretonneux, France"},{"name":"9INSERM U1018, Centre for Research in Epidemiology and Population Health, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"6","key":"2024121014513316400_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"issue":"16","key":"2024121014513316400_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/djt158","article-title":"Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era","volume":"105","author":"Gopal","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"2024121014513316400_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.18704","article-title":"Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: a report from the Australasian Lymphoma Alliance","volume":"201","author":"Lim","year":"2023","journal-title":"Br J Haematol"},{"issue":"18","key":"2024121014513316400_bib4","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","article-title":"Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era","volume":"31","author":"Besson","year":"2017","journal-title":"AIDS Lond. Engl"},{"issue":"5","key":"2024121014513316400_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/hon.2536","article-title":"Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals","volume":"36","author":"Conconi","year":"2018","journal-title":"Hematol Oncol"},{"issue":"3","key":"2024121014513316400_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjh.16176","article-title":"In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study","volume":"188","author":"Philippe","year":"2020","journal-title":"Br J Haematol"},{"issue":"15","key":"2024121014513316400_bib7","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e3283635232","article-title":"Association of early HIV viremia with mortality after HIV-associated lymphoma","volume":"27","author":"Gopal","year":"2013","journal-title":"AIDS Lond. Engl"},{"issue":"17","key":"2024121014513316400_bib8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing treatment of HIV-associated lymphoma","volume":"134","author":"Noy","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2024121014513316400_bib9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1080\/10428194.2017.1403597","article-title":"Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034","volume":"59","author":"Tan","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2024121014513316400_bib10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1055-9965.EPI-11-0037","article-title":"B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma","volume":"20","author":"Breen","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"2024121014513316400_bib11","doi-asserted-by":"crossref","first-page":"e10576","DOI":"10.15252\/emmm.201910576","article-title":"The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma","volume":"11","author":"Hashwah","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2024121014513316400_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/10428194.2011.621566","article-title":"Interleukin-6 plasma levels are modulated by a polymorphism in the NF-\u03baB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma","volume":"53","author":"Giachelia","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024121014513316400_bib13","first-page":"60","article-title":"Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma","volume":"17","author":"Lech-Maranda","year":"2006","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"2024121014513316400_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1751-553X.2007.00951.x","article-title":"Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma","volume":"30","author":"Nacinovi\u0107-Duleti\u0107","year":"2008","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"2024121014513316400_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.2008.01099.x","article-title":"Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy","volume":"81","author":"Kim","year":"2008","journal-title":"Eur J Haematol"},{"key":"2024121014513316400_bib16","doi-asserted-by":"crossref","first-page":"700045","DOI":"10.3389\/fimmu.2021.700045","article-title":"Immune recovery following autologous hematopoietic stem cell transplantation in HIV-related lymphoma patients on the BMT CTN 0803\/AMC 071 trial","volume":"12","author":"Shindiapina","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"2024121014513316400_bib17","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1086\/652866","article-title":"Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma","volume":"50","author":"Simonelli","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024121014513316400_bib18","doi-asserted-by":"crossref","first-page":"37995","DOI":"10.1038\/srep37995","article-title":"B- and T-lymphocyte number and function in HIV+\/HIV- lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation","volume":"6","author":"Bertoli","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"2024121014513316400_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2141.2007.06584.x","article-title":"Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in\u00a0vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation","volume":"137","author":"Nishio","year":"2007","journal-title":"Br J Haematol"},{"issue":"19","key":"2024121014513316400_bib20","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"issue":"25","key":"2024121014513316400_bib21","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin\u2019s lymphoma","volume":"24","author":"Bou\u00e9","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024121014513316400_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2141.2012.09046.x","article-title":"Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP","volume":"157","author":"Ribera","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2024121014513316400_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0609.2006.00693.x","article-title":"Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"77","author":"Nishio","year":"2006","journal-title":"Eur J Haematol"},{"issue":"1","key":"2024121014513316400_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"2024121014513316400_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/cancers14010128","article-title":"Increased production of B-cell activating cytokines and altered peripheral B-cell subset distribution during HIV-related classical Hodgkin lymphoma","volume":"14","author":"Lievin","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"2024121014513316400_bib26","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/art.24722","article-title":"Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment","volume":"60","author":"Muhammad","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2024121014513316400_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/aid.2006.0071","article-title":"Short communication: immune reconstitution after autologous peripheral blood stem cell transplantation in HIV-infected patients: might be better than expected?","volume":"23","author":"Resino","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"2024121014513316400_bib28","first-page":"1229","article-title":"HIV Nef promotes expression of B-lymphocyte stimulator by blood dendritic cells during HIV infection in humans","volume":"211","author":"Chagnon-Choquet","year":"2015","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"2024121014513316400_bib29","doi-asserted-by":"crossref","first-page":"17215","DOI":"10.1038\/s41598-018-35478-1","article-title":"HIV-1 envelope glycoproteins induce the production of TNF-\u03b1 and IL-10 in human monocytes by activating calcium pathway","volume":"8","author":"Plan\u00e8s","year":"2018","journal-title":"Sci Rep"},{"key":"2024121014513316400_bib30","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3389\/fimmu.2017.01338","article-title":"B-cell-activating factor and the B-cell compartment in HIV\/SIV infection","volume":"8","author":"Borhis","year":"2017","journal-title":"Front Immunol"},{"issue":"23","key":"2024121014513316400_bib31","doi-asserted-by":"crossref","first-page":"14883","DOI":"10.1074\/jbc.272.23.14883","article-title":"HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors","volume":"272","author":"Ambrosino","year":"1997","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"2024121014513316400_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.critrevonc.2014.02.004","article-title":"Role of BAFF\/BAFF-R axis in B-cell non-Hodgkin lymphoma","volume":"91","author":"Yang","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"41","key":"2024121014513316400_bib33","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1073\/pnas.0506857102","article-title":"Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy","volume":"102","author":"Popovic","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2024121014513316400_bib34","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2015-11-681411","article-title":"A\u00a0lymphomagenic role for HIV beyond immune suppression?","volume":"127","author":"Dolcetti","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024121014513316400_bib35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4049\/jimmunol.1102321","article-title":"Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors","volume":"188","author":"Kreuzaler","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"2024121014513316400_bib36","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/annonc\/mdm110","article-title":"Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma","volume":"18","author":"Plonquet","year":"2007","journal-title":"Ann Oncol"},{"issue":"4","key":"2024121014513316400_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAD.0b013e32834f30fa","article-title":"Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients","volume":"26","author":"Wyen","year":"2012","journal-title":"AIDS Lond. Engl"},{"issue":"3","key":"2024121014513316400_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1995.13.3.575","article-title":"Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma","volume":"13","author":"Seymour","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024121014513316400_bib39","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/bloodadvances.2020003664","article-title":"Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma","volume":"5","author":"Gholiha","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2024121014513316400_bib40","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2024121014513316400_bib41","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/bloodadvances.2021004286","article-title":"Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP","volume":"5","author":"Eyre","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2024121014513316400_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024121014513316400_bib43","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2019003959","article-title":"Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)","volume":"136","author":"Ramos","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024121014513316400_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2024121014513316400_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ejh.14052","article-title":"Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): a comprehensive review on incidence, risk factors and current management","volume":"112","author":"Galli","year":"2024","journal-title":"Eur J Haematol"},{"issue":"21","key":"2024121014513316400_bib46","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024121014513316400_bib47","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hiv.13514","article-title":"Enabling CAR T-cell therapies for HIV-positive lymphoma patients - a call for action","volume":"24","author":"Hattenhauer","year":"2023","journal-title":"HIV Med"},{"issue":"9","key":"2024121014513316400_bib48","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2352-3026(20)30142-3","article-title":"CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies","volume":"7","author":"Rust","year":"2020","journal-title":"Lancet Haematol"},{"issue":"21","key":"2024121014513316400_bib49","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma","volume":"125","author":"Abramson","year":"2019","journal-title":"Cancer"},{"issue":"suppl 1","key":"2024121014513316400_bib50","doi-asserted-by":"crossref","first-page":"12788","DOI":"10.1182\/blood-2022-157292","article-title":"Trial-in-progress: AMC 112: axicabtagene ciloleucel in relapsed or refractory HIV-associated aggressive B-cell non-Hodgkin lymphoma (NCT05077527)","volume":"140","author":"Epstein-Peterson","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6017\/2345010\/blooda_adv-2024-014116-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6017\/2345010\/blooda_adv-2024-014116-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:52:06Z","timestamp":1733842326000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/6017\/518007\/Immune-reconstitution-and-evolution-of-B-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":50,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014116","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}